
via EPFL
Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
More from: École Polytechnique Fédérale de Lausanne | Lausanne University Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Monoclonal antibody
- Antibodies Market : Projections and Regional Outlook, Depth Study, Analysis, Key Drivers, Top Players, Trends and Forecast 2023-2029
The MarketWatch News Department was not involved in the creation of this content. Feb 03, 2023 (The Expresswire) -- Antibodies Market Size is projected to Reach Multimillion USD by 2029, In comparison ...
- New electrochemical sensing technology enables detection of SARS-CoV-2 antigen-specific antibodies
An obvious way to accomplish this is through the detection of antibodies that the immune system produces against the virus' proteins and variant-specific antigens. Importantly, currently available ...
- With Astonishing CAGR, Monoclonal Antibody Diagnostic Reagents Market Generate Revenue at Significant Rate, 2025
Monoclonal Antibody Diagnostic Reagents Market Report 2023 is spread across 135 pages and provides exclusive vital statistics, data, information, trends and competitive landscape insights in this ...
- Scientists develop AI algorithms to hunt for cancer-fighting antibodies
The screening stage is consuming and expensive, which is where AI algorithms can help. A team of researchers at the University of California San Diego developed a new system that identified an ...
- Immunomodulatory antibodies found to be successful in treating cancer when they have a looser grip
New research from the Centre for Cancer Immunology at the University of Southampton, published ahead of World Cancer Day (4 February), has shown that changing how tightly an antibody binds to a target ...
Go deeper with Google Headlines on:
Monoclonal antibody
[google_news title=”” keyword=”monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 monoclonal antibody
- New electrochemical sensing technology enables detection of SARS-CoV-2 antigen-specific antibodies
The new findings build on a previous study that showed eRapid technology is capable of simultaneously detecting SARS-CoV-2-specific RNA and antibodies on the same electrochemical sensor chips. In ...
- Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies
Lederman said Tonix has obtained an exclusive license for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection. Proactive Studio +1 ...
- Establishment of a rapid and accurate SARS-CoV-2 antigen detection kit able to identify Omicron mutants
They prepared the immunochromatography analysis testing strips, and the monoclonal antibodies were paired successfully ... and incorporating a diluted solution of inactivated SARS-CoV-2. Antibody ...
- Developing the Next Generation of SARS-CoV-2 Vaccines
Researchers are urgently investigating new vaccines to provide more potent and durable protection from COVID-19.
- How monoclonal antibodies lost the fight with new COVID variants
Once a monoclonal antibody finds its soulmate — in the case of COVID, a specific part at the tip of the SARS-CoV-2 virus – it binds to the surface of the antigen. Then, it sends out signals to the ...
Go deeper with Google Headlines on:
SARS-CoV-2 monoclonal antibody
[google_news title=”” keyword=”SARS-CoV-2 monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]